Johnson & Johnson (JNJ) on Monday reported positive results from a network meta-analysis comparing Caplyta with other FDA-approved atypical antipsychotics used as add-on treatments for major depressive disorder in adults.
The analysis, based on data from 10 registrational studies, found that Caplyta ranked highest among approved adjunctive therapies across four efficacy measures.
The study also assessed safety outcomes, with Caplyta showing no statistically significant weight gain versus placebo plus antidepressant therapy and favorable results on certain tolerability measures.
The findings were presented at the Neuroscience Education Institute Spring Congress 2026, held from May 1 to May 3 in Kissimmee.
Caplyta is an atypical antipsychotic approved for use in adults as an add-on treatment with antidepressants for major depressive disorder, schizophrenia and for bipolar depression, either as monotherapy or in combination with lithium or valproate.
JNJ shares closed at $227.19 on Friday, down 1.16%.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.